GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Price-to-Free-Cash-Flow

SNY (Sanofi) Price-to-Free-Cash-Flow : 29.41 (As of Oct. 31, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Sanofi Price-to-Free-Cash-Flow?

As of today (2024-10-31), Sanofi's share price is $52.88. Sanofi's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $1.80. Hence, Sanofi's Price-to-Free-Cash-Flow Ratio for today is 29.41.

The historical rank and industry rank for Sanofi's Price-to-Free-Cash-Flow or its related term are showing as below:

SNY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.63   Med: 17.21   Max: 31.77
Current: 29.66

During the past 13 years, Sanofi's highest Price-to-Free-Cash-Flow Ratio was 31.77. The lowest was 11.63. And the median was 17.21.

SNY's Price-to-Free-Cash-Flow is ranked worse than
55.53% of 515 companies
in the Drug Manufacturers industry
Industry Median: 25.17 vs SNY: 29.66

Sanofi's Free Cash Flow per Share for the six months ended in Jun. 2024 was $-0.20. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $1.80.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Sanofi was -49.00% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 10.80% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 15.40% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 3.60% per year.

During the past 13 years, Sanofi's highest 3-Year average Free Cash Flow per Share Growth Rate was 118.50% per year. The lowest was -15.10% per year. And the median was 3.90% per year.


Sanofi Price-to-Free-Cash-Flow Historical Data

The historical data trend for Sanofi's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Price-to-Free-Cash-Flow Chart

Sanofi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.90 18.49 13.07 13.56 15.59

Sanofi Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 13.56 - 15.59 -

Competitive Comparison of Sanofi's Price-to-Free-Cash-Flow

For the Drug Manufacturers - General subindustry, Sanofi's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanofi's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Sanofi's Price-to-Free-Cash-Flow falls into.



Sanofi Price-to-Free-Cash-Flow Calculation

Sanofi's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=52.88/1.798
=29.41

Sanofi's Share Price of today is $52.88.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sanofi's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $1.80.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Sanofi  (NAS:SNY) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Sanofi Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Sanofi's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Sanofi Business Description

Address
46, avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Sanofi Headlines